AstraZeneca (AZN) Price & Analysis

Compare

804 Followers

AZN Stock Chart & Stats

12532.00p

84.00p(0.78%)

At close: Jan 09 4:00 PM EST

12532.00p

84.00p(0.78%)

Day’s Range― - ―

52-Week Range9,573.51p - 12,972.00p

Previous CloseN/A

Volume91.53K

Average Volume (3M)2.23M

Market Cap

£194.28B

Enterprise Value176.61B

Total Cash (Recent Filing)£7.11B

Total Debt (Recent Filing)£32.84B

Price to Earnings (P/E)30.3

Beta1.09

Next Earnings

Nov 06, 2025

EPS Estimate

1.72

Last Dividend Ex-Date

Aug 07, 2025

Dividend Yield1.67%

Share Statistics

EPS (TTM)1.63

Shares Outstanding1,550,701,900

10 Day Avg. Volume2,301,712

30 Day Avg. Volume2,229,651

Financial Highlights & Ratios

PEG Ratio2.17

Price to Book (P/B)4.98

Price to Sales (P/S)3.83

P/FCF Ratio27.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£14,171.00

Price Target Upside13.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessAZN announced positive results from the TROPION-Breast02 trial which should provide incremental reassurance on the Datroway opportunity.

Innovation And PipelineAstraZeneca has a series of catalysts upcoming which should highlight the innovation led story in a sector weighed down by loss of exclusivity risk.

Sales And Growth PotentialThe valuation looks attractive, with a mid-term guide implying high single-digit sales growth and supporting a rerating to a higher price-to-earnings ratio.

Bears Say

Generic Entry ImpactFarxiga generic entry in the UK might partially offset potential upside.

Market CompetitionFarxiga UK generic entry to offset expectation for VBP timing upside.

AstraZeneca News

Actinium Pharmaceuticals’ ATNM-400 shows superior anti-tumor activity

Actinium Pharmaceuticals (ATNM) announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung...

4h ago

AZN

JNJ

AstraZeneca assumed with a Buy at Jefferies

Jefferies analyst Michael Leuchten assumed coverage of AstraZeneca (AZN) with a Buy rating and 15,000 GBp price target...

5h ago

AZN

Trump Trade: Trump administration prepares new probe into pharma prices

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

5d ago

AZN

AstraZeneca, Amgen’s Tezspire approved in EU as add-on therapy

AstraZeneca (AZN) and Amgen’s (AMGN) Tezspire has been approved in the European Union, EU, as an add-on therapy...

5d ago

AZN

AMGN

Trump admin prepares new probe into U.S. pharma prices, FT says

President Donald Trump’s administration is preparing a new probe into U.S. trading partners over drug pricing, Aime Williams...

5d ago

AZN

AstraZeneca, Daiichi announce results from DESTINY-Breast11 Phase III trial

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce positive results from the DESTINY-Breast11 Phase III trial showed Enhertu followed...

8d ago

AZN

AstraZeneca, Daiichi Sankyo announce Enhertu demonstrated improvement in IDFS

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announced positive results from the DESTINY-Breast05 Phase III trial showed Enhertu demonstrated...

8d ago

AZN

AstraZeneca, Daiichi’s Datroway demonstrated significant improvement in OS, PFS

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announced positive results from the TROPION-Breast02 Phase III trial showed Datroway demonstrated...

8d ago

AZN

AstraZeneca announces improvements in pCR rate in DESTINY-Breast11 trial

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU followed by paclitaxel, trastuzumab and pertuzumab, THP, in...

8d ago

AZN

AstraZeneca, Daiichi announce ENHERTU showed improvement in IDFS

Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU demonstrated a highly statistically significant and clinically meaningful...

8d ago

AZN

AstraZeneca’s Tezspire Gains EU Approval for Chronic Rhinosinusitis with Nasal Polyps

An announcement from AstraZeneca ( ($GB:AZN) ) is now available. AstraZeneca, in collaboration with Amgen, announced the European...

5d ago

AstraZeneca’s Tezspire Gains FDA Approval for New Indication

AstraZeneca ( ($GB:AZN) ) has shared an update. AstraZeneca and Amgen’s Tezspire has been approved by the US...

7d ago

AstraZeneca’s Saphnelo Recommended for EU Approval in Self-Administration Form

The latest update is out from AstraZeneca ( ($GB:AZN) ). AstraZeneca’s Saphnelo (anifrolumab) has been recommended for approval...

7d ago

AstraZeneca Strikes Landmark Deal with US Government to Reduce Drug Costs

AstraZeneca ( ($GB:AZN) ) has shared an announcement. AstraZeneca has announced a historic agreement with the US Government...

14d ago

AZN FAQ

What was AstraZeneca PLC’s price range in the past 12 months?

AstraZeneca PLC lowest share price was 9573.50p and its highest was 12972.00p in the past 12 months.

What is AstraZeneca PLC’s market cap?

AstraZeneca PLC’s market cap is £194.28B.

When is AstraZeneca PLC’s upcoming earnings report date?

AstraZeneca PLC’s upcoming earnings report date is Nov 06, 2025 which is in 10 days.

How were AstraZeneca PLC’s earnings last quarter?

AstraZeneca PLC released its earnings results on Jul 29, 2025. The company reported 1.628p earnings per share for the quarter, beating the consensus estimate of 1.621p by 0.008p.

Is AstraZeneca PLC overvalued?

According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AstraZeneca PLC pay dividends?

AstraZeneca PLC pays a Semiannually dividend of 76.7p which represents an annual dividend yield of 1.67%. See more information on AstraZeneca PLC dividends here

What is AstraZeneca PLC’s EPS estimate?

AstraZeneca PLC’s EPS estimate is 1.72.

How many shares outstanding does AstraZeneca PLC have?

AstraZeneca PLC has 1,550,701,900 shares outstanding.

What happened to AstraZeneca PLC’s price movement after its last earnings report?

AstraZeneca PLC reported an EPS of 1.628p in its last earnings report, beating expectations of 1.621p. Following the earnings report the stock price went up 3.411%.

Which hedge fund is a major shareholder of AstraZeneca PLC?

Currently, no hedge funds are holding shares in GB:AZN

AstraZeneca Stock Smart Score

Neutral

Fundamentals

Return on Equity

20.09%

Trailing 12-Months

Asset Growth

-0.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AstraZeneca PLC

AstraZeneca (AZN) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Headquartered in Cambridge, UK, the company operates in various therapeutic areas including oncology, cardiovascular, renal, metabolism, respiratory, and immunology. AstraZeneca is known for its innovative drug pipeline and significant contributions to the treatment of diseases such as cancer, diabetes, and respiratory conditions. Its portfolio includes well-established products as well as new therapies that leverage cutting-edge research and development.

AstraZeneca (AZN) Earnings & Revenues

Historic Earnings Reports

AZN Stock 12 Month Forecast

Average Price Target

14,171.00p

▲(13.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10245":"10,245p","12184":"12,184p","14123":"14,123p","16062":"16,062p","18001":"18,001p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14171,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10245,12184,14123,16062,18001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12436,12864,13292,13720,14148,14576,15004,15432,15860,16288,16716,17144,17572,{"y":18000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12436,12569.461538461539,12702.923076923076,12836.384615384615,12969.846153846154,13103.307692307691,13236.76923076923,13370.23076923077,13503.692307692309,13637.153846153846,13770.615384615385,13904.076923076922,14037.538461538461,{"y":14171,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12436,12287.076923076924,12138.153846153846,11989.23076923077,11840.307692307691,11691.384615384615,11542.461538461539,11393.538461538461,11244.615384615385,11095.692307692309,10946.76923076923,10797.846153846154,10648.923076923076,{"y":10500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11549.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10788.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10330.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10246.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11103.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11884.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11287.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10534.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10500.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10329.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11026.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11850,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12436,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >